EA201991729A1 - Антитела к tgf-бета и их применение - Google Patents
Антитела к tgf-бета и их применениеInfo
- Publication number
- EA201991729A1 EA201991729A1 EA201991729A EA201991729A EA201991729A1 EA 201991729 A1 EA201991729 A1 EA 201991729A1 EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A1 EA201991729 A1 EA 201991729A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tgf
- antibodies
- beta
- application
- antibody
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- -1 autoimmune diseases Chemical compound 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
В настоящем изобретении предусмотрено улучшенное панспецифичное антитело к TGF-β для лечения состояний, опосредованных TGF-β, в том числе аутоиммунных заболеваний, фиброзных состояний и форм рака. Также предусмотрены способы и пути применения антитела в сочетании с другими иммуномодулирующими средствами, такими как антитело к PD-1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305061 | 2017-01-20 | ||
| PCT/IB2018/000088 WO2018134681A1 (en) | 2017-01-20 | 2018-01-19 | Anti-tgf-beta antibodies and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991729A1 true EA201991729A1 (ru) | 2019-12-30 |
Family
ID=58018036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991729A EA201991729A1 (ru) | 2017-01-20 | 2018-01-19 | Антитела к tgf-бета и их применение |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3571227A1 (ru) |
| EA (1) | EA201991729A1 (ru) |
| WO (1) | WO2018134681A1 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| CA3105333A1 (en) | 2018-07-10 | 2020-01-16 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| JP7540994B2 (ja) | 2018-07-11 | 2024-08-27 | スカラー ロック インコーポレイテッド | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 |
| CN113677711B (zh) | 2019-01-30 | 2025-05-30 | 供石公司 | TGFβ的LTBP复合特异性抑制剂及其用途 |
| IL294650A (en) | 2020-01-11 | 2022-09-01 | Scholar Rock Inc | Tgfbeta inhibitors and use thereof |
| US20230050148A1 (en) | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| KR102811560B1 (ko) * | 2020-03-19 | 2025-05-22 | 제넨테크, 인크. | 동종형 선택적 항-tgf-베타 항체 및 이용 방법 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| TW202304979A (zh) * | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| EP1850873B1 (en) | 2005-02-08 | 2018-11-28 | Genzyme Corporation | Antibodies to tgfbeta |
| SMT201800294T1 (it) | 2011-04-20 | 2018-07-17 | Medimmune Llc | Anticorpi e altre molecole che legano b7-h1 e pd-1 |
| EP3312195B1 (en) * | 2013-03-20 | 2019-10-09 | Genzyme Corporation | Methods for treating osteogenesis imperfecta |
| DK3044234T3 (da) | 2013-09-13 | 2020-05-18 | Beigene Switzerland Gmbh | Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US9988452B2 (en) * | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US10167334B2 (en) * | 2015-04-03 | 2019-01-01 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-BETA and PD-1 antibodies |
-
2018
- 2018-01-19 EA EA201991729A patent/EA201991729A1/ru unknown
- 2018-01-19 EP EP18711394.9A patent/EP3571227A1/en active Pending
- 2018-01-19 WO PCT/IB2018/000088 patent/WO2018134681A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018134681A1 (en) | 2018-07-26 |
| WO2018134681A8 (en) | 2019-10-10 |
| EP3571227A1 (en) | 2019-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991729A1 (ru) | Антитела к tgf-бета и их применение | |
| MX2023002588A (es) | Anticuerpos anti-tgf-beta y su uso. | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| EA201990208A1 (ru) | Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения | |
| EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA201790288A1 (ru) | Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение | |
| MX2019005426A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201790248A1 (ru) | Композиции носитель-антитело и способы их получения и применения | |
| EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| EA201691521A1 (ru) | Антитела к интерлейкину-21 | |
| EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения | |
| EA201992460A1 (ru) | Антитела-агонисты btla и их применение |